New diabetes pill shows promise in Mid-Stage trial

NCT ID NCT07321678

Ongoing Disease control Sponsor: Ascletis Pharma (China) Co., Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental tablet called ASC30 in 100 adults with type 2 diabetes. The goal is to see if it safely lowers blood sugar and helps with weight over 13 weeks compared to a placebo. Participants must have stable weight and a BMI of 23 or higher.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T2DM (TYPE 2 DIABETES MELLITUS)

Contacts and locations

Locations

Ascletis Clinical Site

Riverside, California, 92506, United States
Ascletis Clinical Site

San Jose, California, 95128, United States
Ascletis Clinical Site

Denver, Colorado, 80246, United States
Ascletis Clinical Site

Miami, Florida, 33143, United States
Ascletis Clinical Site

Miami, Florida, 33172, United States
Ascletis Clinical Site

Decatur, Georgia, 30030, United States
Ascletis Clinical Site

Springfield, Missouri, 65802, United States
Ascletis Clinical Site

San Antonio, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.